Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study

被引:2
作者
Masaki, Kou [1 ]
Miyazaki, Motoyasu [1 ,2 ]
Kakimoto, Hideki [1 ]
Fukiage, Yuma [1 ]
Fukue, Haruka [1 ]
Nakashima, Akio [1 ,2 ]
Imakyure, Osamu [1 ,2 ]
Sparreboom, Alex
机构
[1] Fukuoka Univ, Chikushi Hosp, Dept Pharm, Chikushino 8188502, Japan
[2] Fukuoka Univ, Fac Pharmaceut Sci, Fukuoka 8140180, Japan
关键词
immune-related adverse events; immune-checkpoint inhibitor; observational study; ACUTE KIDNEY INJURY; DEATH; CANCER; PNEUMONITIS; NIVOLUMAB; IPILIMUMAB;
D O I
10.3390/jcm12247564
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Immune-checkpoint inhibitors (ICIs) are effective against various cancers; however, immune-related adverse events (irAEs) have been reported and the timing and risk factors are unknown. Therefore, we examined the incidence and timing of irAE occurrence. Methods: Patients who received ICIs at our hospital between 1 April 2016 and 31 March 2020 were enrolled. Patients were classified into an irAE group or non-irAE group. In addition, we examined the onset time and symptoms of irAEs for each ICI type. Results: A total of 80 patients received ICIs, of which 27 (33.8%) developed irAEs. The incidence of irAEs was 35.3% for nivolumab, 35.5% for pembrolizumab, and 28.6% for atezolizumab. The incidence of pneumonitis was 12.5%, 8.8% for dermatologic adverse events, and 6.3% for thyroid dysfunction. The earliest case of onset was after the 1st course, and the latest cases occurred after the 66th course. By the sixth course, 69% of the irAEs occurred. The positive rates for anti-thyroid peroxidase and anti-thyroglobulin antibodies were higher in the irAE group compared to the non-irAE group. Conclusions: Our findings suggest a high probability of irAEs occurring early in ICI treatment, with a diverse range of symptoms. This underscores the need for vigilant monitoring and tailored patient management during the initial courses of ICI therapy.
引用
收藏
页数:12
相关论文
共 33 条
  • [1] Aimono Yuka, 2021, Gan To Kagaku Ryoho, V48, P57
  • [2] Oncology Meets Immunology: The Cancer-Immunity Cycle
    Chen, Daniel S.
    Mellman, Ira
    [J]. IMMUNITY, 2013, 39 (01) : 1 - 10
  • [3] The life-threatening eruptions of immune checkpoint inhibitor therapy
    Coleman, Emily L.
    Olamiju, Brianna
    Leventhal, Jonathan S.
    [J]. CLINICS IN DERMATOLOGY, 2020, 38 (01) : 94 - 104
  • [4] Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study
    Cortazar, Frank B.
    Kibbelaar, Zoe A.
    Glezerman, Ilya G.
    Abudayyeh, Ala
    Mamlouk, Omar
    Motwani, Shveta S.
    Murakami, Naoka
    Herrmann, Sandra M.
    Manohar, Sandhya
    Shirali, Anushree C.
    Kitchlu, Abhijat
    Shirazian, Shayan
    Assal, Amer
    Vijayan, Anitha
    Renaghan, Amanda DeMauro
    Ortiz-Melo, David, I
    Rangarajan, Sunil
    Malik, A. Bilal
    Hogan, Jonathan J.
    Dinh, Alex R.
    Shin, Daniel Sanghoon
    Marrone, Kristen A.
    Mithani, Zain
    Johnson, Douglas B.
    Hosseini, Afrooz
    Uprety, Deekchha
    Sharma, Shreyak
    Gupta, Shruti
    Reynolds, Kerry L.
    Sise, Meghan E.
    Leaf, David E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (02): : 435 - 446
  • [5] Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
    Cortazar, Frank B.
    Marrone, Kristen A.
    Troxell, Megan L.
    Ralto, Kenneth M.
    Hoenig, Melanie P.
    Brahmer, Julie R.
    Le, Dung T.
    Lipson, Evan J.
    Glezerman, Ilya G.
    Wolchok, Jedd
    Cornell, Lynn D.
    Feldman, Paul
    Stokes, Michael B.
    Zapata, Sarah A.
    Hodi, F. Stephen
    Ott, Patrick A.
    Yamashita, Michifumi
    Leaf, David E.
    [J]. KIDNEY INTERNATIONAL, 2016, 90 (03) : 638 - 647
  • [6] Endocrine side effects of cancer immunotherapy
    Cukier, Priscilla
    Santini, Fernando C.
    Scaranti, Mariana
    Hoff, Ana O.
    [J]. ENDOCRINE-RELATED CANCER, 2017, 24 (12) : T331 - T347
  • [7] A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    de Filette, Jeroen
    Andreescu, Corina Emilia
    Cools, Filip
    Bravenboer, Bert
    Velkeniers, Brigitte
    [J]. HORMONE AND METABOLIC RESEARCH, 2019, 51 (03) : 145 - 156
  • [8] Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
    de Filette, Jeroen
    Jansen, Yanina
    Schreuer, Max
    Everaert, Hendrik
    Velkeniers, Brigitte
    Neyns, Bart
    Bravenboer, Bert
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (11) : 4431 - 4439
  • [9] Immune checkpoint inhibitor-related dermatologic adverse events
    Geisler, Amaris N.
    Phillips, Gregory S.
    Barrios, Dulce M.
    Wu, Jennifer
    Leung, Donald Y. M.
    Moy, Andrea P.
    Kern, Jeffrey A.
    Lacouture, Mario E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1255 - 1268
  • [10] Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
    Grouthier, Virginie
    Lebrun-Vignes, Benedicte
    Moey, Melissa
    Johnson, Douglas B.
    Moslehi, Javio J.
    Salem, Joe-Elie
    Bachelot, Anne
    [J]. ONCOLOGIST, 2020, 25 (08) : 696 - 701